药物对比
比较用于偏头痛的注射用单克隆抗体Erenumab（Aimovig）与口服CGRP拮抗剂Atogepant（Qulipta）。两者在给药途径、给药方案和适用性方面的差异。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when selecting between injectable monoclonal antibody and oral gepant CGRP therapies for migraine prevention.
结论
Erenumab and Atogepant both target CGRP receptors for migraine prevention but differ in formulation and administration.